Ativan (Lorazepam) Onsite Taper

No — and you should not attempt it on your own. You arrive on your current prescribed lorazepam dose. Stopping a benzodiazepine abruptly without supervision is genuinely dangerous, which is precisely why the reduction is done onsite: cross-titration to diazepam using Ashton equivalents before reduction. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 21–45 days onsite. That range is driven by lorazepam's short half-life — ≈ 12 hours — and your baseline dose, usually 0.5–6 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The lorazepam discontinuation profile covers: Seizure risk on abrupt cessation; Rebound anxiety, panic, insomnia; Tremor, autonomic instability; Derealization and sensory hypersensitivity. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (50–150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Short half-life means inter-dose withdrawal is common even before a taper begins. No oral hepatic conjugation step (same as oxazepam, temazepam) — different metabolic profile from other benzos. Cross-titration to diazepam makes the taper itself safer.

Yes. Cross-titration to diazepam using Ashton equivalents before reduction. Hyperbolic diazepam taper of 5–10% every 7–14 days. Iboga TA bridge 50–150 mg BID. Continuous cardiac telemetry; EEG monitoring at high-risk steps. Magnesium and electrolyte normalization.

A flood dose of ibogaine HCl is only administered once lorazepam has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.